Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced the addition of two highly experienced individuals to join the Company’s Board of Directors. Hans-Peter Hartung, MD, PhD, FRCP, a world leading clinician and expert in the treatment of Multiple Sclerosis and other neurological diseases, and Timothy Barabe, a proven CFO with global operational and financial expertise, have each been appointed to the Company's Board of Directors, effective March 19 th.
“We are thrilled to be adding such esteemed individuals to complement our existing Board,” commented Neil K. Warma, Opexa’s President and CEO. “Hans Peter has been a critical member of our Scientific Advisory Board for several years and has been instrumental to the design of the Phase IIb trial we are currently running in Secondary Progressive MS. He is a recognized worldwide leader in the field of clinical immunology with a strong standing in the MS and neurology fields. Complementing the addition of Hans Peter, Tim brings a wealth of expertise in operations and finance, including in international settings. Tim served in senior executive roles in Novartis, including as CFO of its Sandoz Generics business unit, and CFO of Affymetrix and Human Genome Sciences, combining knowledge from both the pharmaceutical and biotech industries.”
“I am honored to join Opexa's Board and work closely with an outstanding management team,” commented Professor Hartung. “I believe that Opexa’s novel personalized T-cell immunotherapy platform has tremendous potential in MS and possibly in other immune mediated diseases. I look forward to contributing to the Company.”
Mr. Barabe remarked, “I am thrilled to be joining such an innovative and forward-looking company. I am impressed by the potential of Tcelna and I believe my operational and financial experience can be useful to the Company’s future.”